Bernstein Liebhard LLP Reports On New Study Supporting Link Between Actos And Bladder Cancer
Bernstein Liebhard LLP, a nationwide law firm representing clients who have been injured by dangerous drugs and defective medical devices, reports on a May 31, 2012 study published in the British Medical Journal (“BMJ”) concerning the link between Actos and bladder cancer. The study, conducted by Canadian researchers, found that patients with type 2 diabetes who took Actos had an 83 percent increased rate of developing bladder cancer. The risk increased to 88 percent for those who took Actos for two years or longer—or those who consumed 28,000 milligrams or more. The study analyzed data from over 115,000 British patients who were treated with Actos between 1988 and 2009. Of those, 470 patients were diagnosed with bladder cancer. Researchers found that the risk of developing bladder cancer from Actos was 89 cases per 100,000 people, which jumped to 137 cases per 100,000 for those who took 28,000 milligrams or more. In the general U.K. population, the rate of bladder cancer in those 65 or older is 73 cases per 100,000.
Actos And Bladder Cancer Link Alarms Doctors And Patients
“We believe physicians, patients and regulatory agencies should be aware of this association when assessing the overall risks and benefits of this therapy,” lead researcher Laurent Azoulay, from the Center for Clinical Epidemiology at the Lady Davis Institute at Jewish General Hospital in Montreal, told HealthDay News. Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City, said: “We need to be more careful with the use of this medication…if there are more studies like this, we will not be using this medication.”
This latest study confirms earlier concerns about Actos side effects. In May 2011, the U.S. Food and Drug Administration (“FDA”) published a study, which concluded that there is a link between Actos and bladder cancer; the FDA added a warning label to alert users about Actos side effects. While Actos is still available in the United States, it has been recalled in both Germany and France.
Individuals who experienced Actos side effects such as bladder cancer are filing lawsuits against the drug manufacturer, Takeda Pharmaceuticals, alleging that the company failed to adequately research and warn patients about risks and side effects. Those who developed bladder cancer as a result of taking Actos may be able to collect compensation for medical expenses, lost wages, pain and suffering, and more. The lawyers at Bernstein Liebhard LLP are currently evaluating and investigating potential Actos claims. For more information about Actos side effects, visit www.consumerinjurylawyers.com.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.
Bernstein Liebhard LLP 10 East 40th Street New York, New York 10016 (877) 779-1414
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.